<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928224</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-818-302</org_study_id>
    <secondary_id>2015-005805-35</secondary_id>
    <nct_id>NCT02928224</nct_id>
  </id_info>
  <brief_title>Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer</brief_title>
  <acronym>BEACON CRC</acronym>
  <official_title>A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib +
      cetuximab plus or minus binimetinib versus Investigator's choice of either
      irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose
      disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study
      contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib +
      binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Safety Lead-in) Number of Participants With Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (up to 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Safety Lead-in) Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>Refer to AE/SAE section for additional data that were measured and analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Phase 3) Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Response Rate (ORR) by Investigator</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Response Rate (ORR) by BICR</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>ORR per RECIST, v1.1, defined as the number of patients achieving an overall best response of CR or partial response (PR) divided by the total number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Duration of Response (DOR) by Investigator</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Duration of Response (DOR) by BICR</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>DOR defined as the time from first radiographic evidence of response to the earliest documented disease progression or death due to underlying disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Time to Response by Investigator</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Time to Response by BICR</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Progression-free Survival (PFS) by Investigator</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Progression-free Survival (PFS) by BICR</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>PFS defined as the time from first dose to the earliest documented disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Patients (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>FACT-C is a well-characterized and commonly used questionnaire that belongs to the Functional Assessment of Chronic Illness Therapy Measurement System (FACIT). The FACT-G (G for general) questionnaire (27 questions) constitutes the core of all subscales and is applicable to all tumor types. The FACT-C questionnaire contains 9 additional questions on symptoms specific to CRC, 2 of which are only answered by patients with ostomy appliances. These 9 CRC-specific questions are categorized as &quot;additional concerns&quot; on the questionnaire and constitute the &quot;colorectal cancer subscale&quot; score. The patient self-reports his/her QoL for the previous 7 days. The overall score is calculated across all items and a higher score reflects better quality of life (QoL). The table summarizes the functional well-being subscale, the individual questions are linearly scaled and combined to form the functional well-being subscale score, which ranges from 0-28 (higher is better QoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Change From Baseline in the EuroQol-5D-5L (EQ-5D-5L) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the patient and ranges from 0 to 100 (higher is better quality health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Change From Baseline in the Patient Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>The PGIC is a measure of patients' perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other patient reported outcome (PROs). For this assessment, patients answered the following question: &quot;Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Cetuximab</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Encorafenib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Metabolite of Binimetinib (AR00426032)</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032)</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032)</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib</measure>
    <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
    <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib</measure>
    <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
    <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab</measure>
    <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
    <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">702</enrollment>
  <condition>BRAF V600E-mutant Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encorafenib + binimetinib + cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doublet Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encorafenib + cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib</intervention_name>
    <description>Orally, once daily.</description>
    <arm_group_label>Doublet Arm</arm_group_label>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Binimetinib</intervention_name>
    <description>Orally, twice daily.</description>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Doublet Arm</arm_group_label>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>FA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Age ≥ 18 years at time of informed consent

          -  Histologically- or cytologically-confirmed CRC that is metastatic

          -  Presence of BRAFV600E in tumor tissue as previously determined by a local assay at any
             time prior to Screening or by the central laboratory

          -  Progression of disease after 1 or 2 prior regimens in the metastatic setting

          -  Evidence of measurable or evaluable non-measurable disease per RECIST, v1.1

          -  Adequate bone marrow, cardiac, kidney and liver function

          -  Able to take oral medications

          -  Female patients are either postmenopausal for at least 1 year, are surgically sterile
             for at least 6 weeks, or must agree to take appropriate precautions to avoid pregnancy
             from screening through follow-up if of childbearing potential

          -  Males must agree to take appropriate precautions to avoid fathering a child from
             screening through follow-up

        Key Exclusion Criteria:

          -  Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab, panitumumab or other
             epidermal growth factor receptor (EGFR) inhibitors

          -  Prior irinotecan hypersensitivity or toxicity that would suggest an inability to
             tolerate irinotecan 180 mg/m2 every 2 weeks

          -  Symptomatic brain metastasis or leptomeningeal disease

          -  History or current evidence of retinal vein occlusion or current risk factors for
             retinal vein occlusion (e.g., uncontrolled glaucoma or ocular hypertension, history of
             hyperviscosity or hypercoagulability syndromes)

          -  Known history of acute or chronic pancreatitis

          -  History of chronic inflammatory bowel disease or Crohn's disease requiring medical
             intervention (immunomodulatory or immunosuppressive medications or surgery) ≤12 months
             prior to randomization

          -  Uncontrolled blood pressure despite medical treatment

          -  Impaired GI function or disease that may significantly alter the absorption of
             encorafenib or binimetinib (e.g., ulcerative diseases, uncontrolled vomiting,
             malabsorption syndrome, small bowel resection with decreased intestinal absorption)

          -  Concurrent or previous other malignancy within 5 years of study entry, except cured
             basal or squamous cell skin cancer, superficial bladder cancer, prostate
             intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or
             indolent malignancy

          -  History of thromboembolic or cerebrovascular events ≤ 6 months prior to starting study
             treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein
             thrombosis or pulmonary emboli

          -  Concurrent neuromuscular disorder that is associated with the potential of elevated
             creatine (phosphor)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy,
             amyotrophic lateral sclerosis, spinal muscular atrophy)

          -  Residual common terminology criteria for adverse events (CTCAE) ≥ Grade 2 toxicity
             from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2
             neuropathy

          -  Known history of HIV infection

          -  Active hepatitis B or hepatitis C infection

          -  Known history of Gilbert's syndrome

          -  Known contraindication to receive cetuximab or irinotecan at the planned doses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Array BioPharma, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>303-381-6604</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group, Inc. - Corona</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope - Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California (USC) Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward General Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30332</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Cancer Center</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Health Care - University of Iowa Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MGH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer CTR Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer CTR</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Health</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, P.S.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Pergamino</city>
        <state>Buenos Aires</state>
        <zip>B2700CPM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Córdoba</city>
        <state>Cordoba</state>
        <zip>X5004FHP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>La Pampa</state>
        <zip>L6300EAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>San Miguel De Tucumán</city>
        <state>Tucuman</state>
        <zip>T400GTB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>La Rioja</city>
        <zip>5300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Steyr</city>
        <state>Oberösterreich</state>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Wels</city>
        <state>Oberösterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerpen</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array Biopharma Investigative Site</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Verviers</city>
        <state>Liege</state>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Libramont-Chevigny</city>
        <state>Luxembourg</state>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Roeselare</city>
        <state>West-Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Sites (2)</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Cachoeiro de Itapemirim</city>
        <state>Espírito Santo</state>
        <zip>29308-14</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Caxias do Sul</city>
        <state>Rio Grande Do Sul</state>
        <zip>95070-560</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Lajeado</city>
        <state>Rio Grande Do Sul</state>
        <zip>95900-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Pelotas</city>
        <state>Rio Grande Do Sul</state>
        <zip>96015-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Ivestigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90050-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Itajaí</city>
        <state>Santa Catarina</state>
        <zip>88301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Jose Do Rio Preto</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Sorocaba</city>
        <state>São Paulo</state>
        <zip>18030-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Passo Fundo</city>
        <zip>RS 99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Pôrto Alegre</city>
        <zip>RS 90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01236-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Temuco</city>
        <state>Araucanía</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>Brno-město</state>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Hradec Králové</city>
        <state>Královéhradecký Kraj</state>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Praha</city>
        <zip>18081</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Odense</city>
        <state>South Denmark</state>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Reims</city>
        <state>Cedex</state>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Villejuif</city>
        <state>Il-de-France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Avignon</city>
        <state>Vaucluse</state>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Périgueux</city>
        <zip>24004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Schweinfurt</city>
        <state>Bayern</state>
        <zip>97422</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Hannöver</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Worms</city>
        <state>Rheinland-Pfalz</state>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Tübingen</city>
        <state>Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Kaposvár</city>
        <state>Somogy</state>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arrray BioPharma Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>H-8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Beer Sheva</city>
        <state>HaDarom</state>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Kfar Saba</city>
        <state>HaMerkaz</state>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Petah Tikva</city>
        <state>HaMerkaz</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <state>Hamerkaz</state>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Monza</city>
        <state>Milano</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Sites (2)</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Sites (2)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Haikodo</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Kanazawa</city>
        <state>Isikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Amagasaki</city>
        <state>Osaka</state>
        <zip>660-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Tsukiji</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1347</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Busan</city>
        <state>Busan Gwang'yeogsi</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggido</state>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggido</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Jeollanam-do</city>
        <state>Jeonranamdo</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Teugbyeolsi</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Distrito Federal</city>
        <state>Col Roma</state>
        <zip>6760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>México</city>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Noord-Holland</city>
        <state>Amsterdam</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Amhem</city>
        <state>Gelderland</state>
        <zip>6883</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Heidelberglaan</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Limburg</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>N-0785</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Otwock</city>
        <state>Mazowieckie</state>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Sites (2)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Brzozów</city>
        <state>Podkarpackie</state>
        <zip>36-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Elbląg</city>
        <state>Warminsko-mazurskie</state>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>61-485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Obninsk</city>
        <state>Kaluzhskaya Oblast'</state>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Kursk</city>
        <state>Kurski Region</state>
        <zip>305035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Sites (2)</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>San Sebastián</city>
        <state>Guipúzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Balears</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Madrid</city>
        <state>Sancchinarro</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array Biopharma Investigative Sites (2)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Burgos</city>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arrray BioPharma Investigative Sites (2)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Taichung</city>
        <state>Changhua</state>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Linkou</city>
        <state>Taoyuan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site (2)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Edime</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>İstanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>İzmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>İzmir</city>
        <zip>35575</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Malatya</city>
        <zip>44400</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Dnipropetrovs'ka Oblast'</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Vinnytsya</city>
        <state>Vinnyts'ka Oblast'</state>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Uzhgorod</city>
        <state>Zakarpats'ka Oblast'</state>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02096</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Aberdeen</city>
        <state>Aberdeenshire</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Hammersmith</city>
        <state>London</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <results_first_submitted>May 6, 2020</results_first_submitted>
  <results_first_submitted_qc>June 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2020</results_first_posted>
  <disposition_first_submitted>December 19, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>December 19, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 20, 2019</disposition_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>BRAF</keyword>
  <keyword>BRAFV600E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02928224/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02928224/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were at least 18 years of age with confirmed metastatic colorectal cancer (CRC) whose disease had progressed after 1 or 2 prior regimens in the metastatic setting and whose tumor tissue was BRAF V600E-mutant as previously determined by a local assay at any time prior to Screening</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Combined Safety Lead-in</title>
          <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="P2">
          <title>Phase 3: Triplet Arm</title>
          <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="P3">
          <title>Phase 3: Doublet Arm</title>
          <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="P4">
          <title>Phase 3:Control Arm</title>
          <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="224"/>
                <participants group_id="P3" count="220"/>
                <participants group_id="P4" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="224"/>
                <participants group_id="P3" count="220"/>
                <participants group_id="P4" count="221"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized, Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="103"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Changes in Patient's Condition</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dose Interruptions&gt;28</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Decision to Discontinue Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not listed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population consists of the Full Analysis Set (FAS). For patients in the CSLI, the FAS includes all patients who received at least 1 dose of study drug and had at least 1 post treatment assessment, which may include death. For the randomized Phase 3 portion of the study, the FAS consists of all randomized patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Combined Safety Lead-in (CSLI)</title>
          <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="B2">
          <title>Phase 3: Triplet Arm</title>
          <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="B3">
          <title>Phase 3: Doublet Arm</title>
          <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="B4">
          <title>Phase 3:Control Arm</title>
          <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="224"/>
            <count group_id="B3" value="220"/>
            <count group_id="B4" value="221"/>
            <count group_id="B5" value="702"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="149"/>
                    <measurement group_id="B5" value="450"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="10.34"/>
                    <measurement group_id="B2" value="59.5" spread="11.65"/>
                    <measurement group_id="B3" value="60.2" spread="11.65"/>
                    <measurement group_id="B4" value="58.4" spread="12.07"/>
                    <measurement group_id="B5" value="59.3" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="127"/>
                    <measurement group_id="B5" value="373"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="183"/>
                    <measurement group_id="B4" value="172"/>
                    <measurement group_id="B5" value="579"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="445"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rest of World (includes Mexico)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group Performance Status (ECOG PS) at Baseline</title>
          <description>ECOG PS was used to assess the physical health of patients, and ranges from 0 (most active) to 5 (dead). Frequency counts and percentages of patients in each score category were provided by treatment arm and assessment visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0-Fully active</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="108"/>
                    <measurement group_id="B5" value="358"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1-Restircted in physically strenuous activity</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="340"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2-Ambulatory and capable of all self-care</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Tumor Location</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Left Colon</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="241"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Right Colon</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="378"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Left and Right Colon</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Tumor Removed</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Completely Resected</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="122"/>
                    <measurement group_id="B5" value="398"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partially Resected/Unresected</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Organs Involved</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&gt;=2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="370"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sites of Metastases</title>
          <units>sites</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="128"/>
                    <measurement group_id="B5" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NodePeritoneum/Omentum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>(Safety Lead-in) Number of Participants With Dose-limiting Toxicities (DLTs)</title>
        <time_frame>Cycle 1 (up to 28 days)</time_frame>
        <population>The Dose-determining Set (DDS) consisted of all CSLI patients from the Safety Set who either completed a minimum exposure requirement (received ≥ 75% dose intensity of the planned dose for each binimetinib, encorafenib and cetuximab) and had sufficient safety evaluations or experienced a dose-limiting toxicity (DLT).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in (CSLI)</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Number of Participants With Dose-limiting Toxicities (DLTs)</title>
          <population>The Dose-determining Set (DDS) consisted of all CSLI patients from the Safety Set who either completed a minimum exposure requirement (received ≥ 75% dose intensity of the planned dose for each binimetinib, encorafenib and cetuximab) and had sufficient safety evaluations or experienced a dose-limiting toxicity (DLT).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Safety Lead-in) Number of Participants With Adverse Events (AEs)</title>
        <description>Refer to AE/SAE section for additional data that were measured and analyzed.</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Safety Set consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. Patients were analyzed according to treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Number of Participants With Adverse Events (AEs)</title>
          <description>Refer to AE/SAE section for additional data that were measured and analyzed.</description>
          <population>The Safety Set consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. Patients were analyzed according to treatment received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)</title>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Safety Set consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. Patients were analyzed according to treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)</title>
          <population>The Safety Set consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. Patients were analyzed according to treatment received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm</title>
          <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03" lower_limit="8.02" upper_limit="11.43"/>
                    <measurement group_id="O2" value="5.42" lower_limit="4.76" upper_limit="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Phase 3) Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="18.2" upper_limit="35.3"/>
                    <measurement group_id="O2" value="2" lower_limit=".2" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Response Rate (ORR) by Investigator</title>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Safety Lead-in (SLI) Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Response Rate (ORR) by Investigator</title>
          <population>The Safety Lead-in (SLI) Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="35.5" upper_limit="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Response Rate (ORR) by BICR</title>
        <description>ORR per RECIST, v1.1, defined as the number of patients achieving an overall best response of CR or partial response (PR) divided by the total number of patients</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Response Rate (ORR) by BICR</title>
          <description>ORR per RECIST, v1.1, defined as the number of patients achieving an overall best response of CR or partial response (PR) divided by the total number of patients</description>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="25.5" upper_limit="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Duration of Response (DOR) by Investigator</title>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Duration of Response (DOR) by Investigator</title>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" lower_limit="4.17" upper_limit="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Duration of Response (DOR) by BICR</title>
        <description>DOR defined as the time from first radiographic evidence of response to the earliest documented disease progression or death due to underlying disease</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Duration of Response (DOR) by BICR</title>
          <description>DOR defined as the time from first radiographic evidence of response to the earliest documented disease progression or death due to underlying disease</description>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.15" lower_limit="2.79" upper_limit="NA">NA= not reached. Insufficient number of participants with events to calculate the upper limit of the 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Time to Response by Investigator</title>
        <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Time to Response by Investigator</title>
          <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="1.38" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Time to Response by BICR</title>
        <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Time to Response by BICR</title>
          <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="1.38" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Progression-free Survival (PFS) by Investigator</title>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Progression-free Survival (PFS) by Investigator</title>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.08" lower_limit="5.59" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Progression-free Survival (PFS) by BICR</title>
        <description>PFS defined as the time from first dose to the earliest documented disease progression or death due to any cause</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Progression-free Survival (PFS) by BICR</title>
          <description>PFS defined as the time from first dose to the earliest documented disease progression or death due to any cause</description>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" lower_limit="4.44" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm</title>
          <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.41" lower_limit="7.46" upper_limit="11.04"/>
                    <measurement group_id="O2" value="5.42" lower_limit="4.76" upper_limit="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm</title>
          <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03" lower_limit="8.02" upper_limit="11.43"/>
                    <measurement group_id="O2" value="8.41" lower_limit="7.46" upper_limit="11.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" lower_limit="4.14" upper_limit="5.19"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.45" upper_limit="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" lower_limit="4.24" upper_limit="5.36"/>
                    <measurement group_id="O2" value="1.58" lower_limit="1.51" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" lower_limit="3.71" upper_limit="5.36"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.45" upper_limit="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" lower_limit="4.04" upper_limit="5.36"/>
                    <measurement group_id="O2" value="1.58" lower_limit="1.51" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" lower_limit="4.14" upper_limit="5.19"/>
                    <measurement group_id="O2" value="4.21" lower_limit="3.71" upper_limit="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" lower_limit="4.24" upper_limit="5.36"/>
                    <measurement group_id="O2" value="4.27" lower_limit="4.04" upper_limit="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="13.4" upper_limit="29"/>
                    <measurement group_id="O2" value="2" lower_limit=".2" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="18.2" upper_limit="35.3"/>
                    <measurement group_id="O2" value="23" lower_limit="13.4" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="2.96" upper_limit="9.69"/>
                    <measurement group_id="O2" value="NA" lower_limit="2.56" upper_limit="NA">NA= not reached. Insufficient number of participants with events to calculate the upper limit of the 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="3.29" upper_limit="6.57"/>
                    <measurement group_id="O2" value="5.75" lower_limit="2.56" upper_limit="NA">NA= not reached. Insufficient number of participants with events to calculate the upper limit of the 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" lower_limit="4.07" upper_limit="8.28"/>
                    <measurement group_id="O2" value="NA" lower_limit="2.56" upper_limit="NA">NA= not reached. Insufficient number of participants with events to calculate the upper limit of the 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" lower_limit="3.65" upper_limit="6.74"/>
                    <measurement group_id="O2" value="5.75" lower_limit="2.56" upper_limit="NA">NA= not reached. Insufficient number of participants with events to calculate the upper limit of the 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="2.96" upper_limit="9.69"/>
                    <measurement group_id="O2" value="6.06" lower_limit="4.07" upper_limit="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="3.29" upper_limit="6.57"/>
                    <measurement group_id="O2" value="5.70" lower_limit="3.65" upper_limit="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="1.41" upper_limit="1.51"/>
                    <measurement group_id="O2" value="1.45" lower_limit="1.41" upper_limit="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.41" upper_limit="1.51"/>
                    <measurement group_id="O2" value="2.63" lower_limit="1.45" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.41" upper_limit="1.58"/>
                    <measurement group_id="O2" value="1.45" lower_limit="1.41" upper_limit="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.41" upper_limit="1.54"/>
                    <measurement group_id="O2" value="2.63" lower_limit="1.45" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="1.41" upper_limit="1.51"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1.41" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.41" upper_limit="1.51"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1.41" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Patients (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
        <description>The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.</description>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O3">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Patients (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
          <description>The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.</description>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="201"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" spread="22.18"/>
                    <measurement group_id="O2" value="60.7" spread="21.33"/>
                    <measurement group_id="O3" value="62.8" spread="21.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="13.44"/>
                    <measurement group_id="O2" value="-4.3" spread="16.27"/>
                    <measurement group_id="O3" value="-3.4" spread="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="180"/>
                    <count group_id="O3" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="19.06"/>
                    <measurement group_id="O2" value="3.8" spread="18.46"/>
                    <measurement group_id="O3" value="-1.9" spread="22.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="18.86"/>
                    <measurement group_id="O2" value="3.5" spread="19.96"/>
                    <measurement group_id="O3" value="-0.2" spread="24.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="15.63"/>
                    <measurement group_id="O2" value="4.2" spread="22.17"/>
                    <measurement group_id="O3" value="1.4" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="18.66"/>
                    <measurement group_id="O2" value="4.3" spread="22.09"/>
                    <measurement group_id="O3" value="-2.2" spread="22.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="16.76"/>
                    <measurement group_id="O2" value="5.6" spread="23.25"/>
                    <measurement group_id="O3" value="-4.5" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="16.01"/>
                    <measurement group_id="O2" value="4.3" spread="21.77"/>
                    <measurement group_id="O3" value="1.7" spread="12.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="14.83"/>
                    <measurement group_id="O2" value="4.2" spread="16.98"/>
                    <measurement group_id="O3" value="0.0" spread="27.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="17.74"/>
                    <measurement group_id="O2" value="-5.6" spread="16.44"/>
                    <measurement group_id="O3" value="-4.8" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="17.90"/>
                    <measurement group_id="O2" value="-2.8" spread="16.97"/>
                    <measurement group_id="O3" value="2.1" spread="20.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="20.38"/>
                    <measurement group_id="O2" value="3.9" spread="15.31"/>
                    <measurement group_id="O3" value="33.3" spread="NA">Number analyzed is 1 so standard deviation (SD) is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="22.41"/>
                    <measurement group_id="O2" value="-4.6" spread="13.77"/>
                    <measurement group_id="O3" value="4.2" spread="53.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="20.41"/>
                    <measurement group_id="O2" value="-3.2" spread="14.25"/>
                    <measurement group_id="O3" value="0.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="24.26"/>
                    <measurement group_id="O2" value="-6.0" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="33.63"/>
                    <measurement group_id="O2" value="2.8" spread="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="42.08"/>
                    <measurement group_id="O2" value="-5.6" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.8" spread="20.97"/>
                    <measurement group_id="O2" value="-2.8" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-8.3" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-8.3" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-8" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-16.7" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 22 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-16.7" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="22.66"/>
                    <measurement group_id="O2" value="-13.1" spread="21.61"/>
                    <measurement group_id="O3" value="-15.5" spread="27.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Follow Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.4" spread="22.51"/>
                    <measurement group_id="O2" value="-10.4" spread="15.96"/>
                    <measurement group_id="O3" value="-24.6" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
        <description>FACT-C is a well-characterized and commonly used questionnaire that belongs to the Functional Assessment of Chronic Illness Therapy Measurement System (FACIT). The FACT-G (G for general) questionnaire (27 questions) constitutes the core of all subscales and is applicable to all tumor types. The FACT-C questionnaire contains 9 additional questions on symptoms specific to CRC, 2 of which are only answered by patients with ostomy appliances. These 9 CRC-specific questions are categorized as &quot;additional concerns&quot; on the questionnaire and constitute the &quot;colorectal cancer subscale&quot; score. The patient self-reports his/her QoL for the previous 7 days. The overall score is calculated across all items and a higher score reflects better quality of life (QoL). The table summarizes the functional well-being subscale, the individual questions are linearly scaled and combined to form the functional well-being subscale score, which ranges from 0-28 (higher is better QoL).</description>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O3">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
          <description>FACT-C is a well-characterized and commonly used questionnaire that belongs to the Functional Assessment of Chronic Illness Therapy Measurement System (FACIT). The FACT-G (G for general) questionnaire (27 questions) constitutes the core of all subscales and is applicable to all tumor types. The FACT-C questionnaire contains 9 additional questions on symptoms specific to CRC, 2 of which are only answered by patients with ostomy appliances. These 9 CRC-specific questions are categorized as &quot;additional concerns&quot; on the questionnaire and constitute the &quot;colorectal cancer subscale&quot; score. The patient self-reports his/her QoL for the previous 7 days. The overall score is calculated across all items and a higher score reflects better quality of life (QoL). The table summarizes the functional well-being subscale, the individual questions are linearly scaled and combined to form the functional well-being subscale score, which ranges from 0-28 (higher is better QoL).</description>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="199"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="6.22"/>
                    <measurement group_id="O2" value="16.2" spread="5.9"/>
                    <measurement group_id="O3" value="16.8" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.36"/>
                    <measurement group_id="O2" value="-0.9" spread="4.06"/>
                    <measurement group_id="O3" value="-1.4" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="176"/>
                    <count group_id="O3" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="4.28"/>
                    <measurement group_id="O2" value="-0.6" spread="5.08"/>
                    <measurement group_id="O3" value="-0.9" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.15"/>
                    <measurement group_id="O2" value="-0.2" spread="5.23"/>
                    <measurement group_id="O3" value="-0.7" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="4.53"/>
                    <measurement group_id="O2" value="-0.1" spread="4.66"/>
                    <measurement group_id="O3" value="-1.8" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="6.4"/>
                    <measurement group_id="O2" value="-0.2" spread="4.5"/>
                    <measurement group_id="O3" value="-1.6" spread="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="6.05"/>
                    <measurement group_id="O2" value="0.6" spread="4.56"/>
                    <measurement group_id="O3" value="-1.9" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="5.85"/>
                    <measurement group_id="O2" value="-0.1" spread="4.70"/>
                    <measurement group_id="O3" value="-0.5" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="6.35"/>
                    <measurement group_id="O2" value="0.2" spread="4.24"/>
                    <measurement group_id="O3" value="-2.1" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="4.32"/>
                    <measurement group_id="O2" value="-0.8" spread="3.74"/>
                    <measurement group_id="O3" value="-2.6" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="4.76"/>
                    <measurement group_id="O2" value="-1.3" spread="3.59"/>
                    <measurement group_id="O3" value="0.5" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="4.47"/>
                    <measurement group_id="O2" value="-0.5" spread="4.65"/>
                    <measurement group_id="O3" value="-4.5" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="4.93"/>
                    <measurement group_id="O2" value="-1.1" spread="4.61"/>
                    <measurement group_id="O3" value="-4.5" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="6.76"/>
                    <measurement group_id="O2" value="-3.2" spread="5.34"/>
                    <measurement group_id="O3" value="-8.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="5.22"/>
                    <measurement group_id="O2" value="-4.0" spread="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="6.85"/>
                    <measurement group_id="O2" value="-1.5" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.02"/>
                    <measurement group_id="O2" value="-0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="5.51"/>
                    <measurement group_id="O2" value="-0.7" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-3.0" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-6.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-5.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0"/>
                    <measurement group_id="O2" value="-5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 22 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-12.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-9.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="4.84"/>
                    <measurement group_id="O2" value="-2.2" spread="5.14"/>
                    <measurement group_id="O3" value="-3.1" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Follow Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="6.44"/>
                    <measurement group_id="O2" value="-0.8" spread="5.42"/>
                    <measurement group_id="O3" value="-4.2" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Change From Baseline in the EuroQol-5D-5L (EQ-5D-5L) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
        <description>The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the patient and ranges from 0 to 100 (higher is better quality health).</description>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O3">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Change From Baseline in the EuroQol-5D-5L (EQ-5D-5L) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
          <description>The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the patient and ranges from 0 to 100 (higher is better quality health).</description>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="203"/>
                    <count group_id="O3" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" spread="19.03"/>
                    <measurement group_id="O2" value="66.5" spread="19.51"/>
                    <measurement group_id="O3" value="68.3" spread="19.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="10.89"/>
                    <measurement group_id="O2" value="-0.9" spread="14.09"/>
                    <measurement group_id="O3" value="-2.1" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="181"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="14.74"/>
                    <measurement group_id="O2" value="1.9" spread="14.81"/>
                    <measurement group_id="O3" value="-2.4" spread="17.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="150"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="13.94"/>
                    <measurement group_id="O2" value="4.2" spread="17.32"/>
                    <measurement group_id="O3" value="-1.4" spread="17.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="13.06"/>
                    <measurement group_id="O2" value="5.6" spread="14.87"/>
                    <measurement group_id="O3" value="-0.4" spread="15.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="14.66"/>
                    <measurement group_id="O2" value="5.1" spread="15.11"/>
                    <measurement group_id="O3" value="2.5" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="13.33"/>
                    <measurement group_id="O2" value="2.9" spread="16.84"/>
                    <measurement group_id="O3" value="-3.6" spread="13.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="13.64"/>
                    <measurement group_id="O2" value="3.6" spread="16.71"/>
                    <measurement group_id="O3" value="2.4" spread="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="10.77"/>
                    <measurement group_id="O2" value="2.0" spread="16.11"/>
                    <measurement group_id="O3" value="-2.8" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="15.16"/>
                    <measurement group_id="O2" value="-4.0" spread="12.99"/>
                    <measurement group_id="O3" value="-8.1" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="13.34"/>
                    <measurement group_id="O2" value="-8.1" spread="13.68"/>
                    <measurement group_id="O3" value="-1.8" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="13.87"/>
                    <measurement group_id="O2" value="-0.1" spread="10.15"/>
                    <measurement group_id="O3" value="4.0" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="20.11"/>
                    <measurement group_id="O2" value="-0.6" spread="11.67"/>
                    <measurement group_id="O3" value="1.5" spread="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="17.17"/>
                    <measurement group_id="O2" value="-4.1" spread="14.41"/>
                    <measurement group_id="O3" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="18.06"/>
                    <measurement group_id="O2" value="-0.4" spread="13.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="14.67"/>
                    <measurement group_id="O2" value="4.2" spread="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="24.87"/>
                    <measurement group_id="O2" value="3.3" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="20.21"/>
                    <measurement group_id="O2" value="1.7" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-3.3" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-5.5" spread="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-5.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 22 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-5.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-5.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="17.40"/>
                    <measurement group_id="O2" value="-8.0" spread="18.99"/>
                    <measurement group_id="O3" value="-12.7" spread="21.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Follow Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="20.23"/>
                    <measurement group_id="O2" value="-5.9" spread="20.18"/>
                    <measurement group_id="O3" value="-11.0" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Change From Baseline in the Patient Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
        <description>The PGIC is a measure of patients' perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other patient reported outcome (PROs). For this assessment, patients answered the following question: &quot;Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse.&quot;</description>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O3">
            <title>Phase 3:Control Arm</title>
            <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Change From Baseline in the Patient Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
          <description>The PGIC is a measure of patients' perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other patient reported outcome (PROs). For this assessment, patients answered the following question: &quot;Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse.&quot;</description>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="152"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.30"/>
                    <measurement group_id="O2" value="3.8" spread="1.30"/>
                    <measurement group_id="O3" value="3.9" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.93"/>
                    <measurement group_id="O2" value="0.1" spread="1.21"/>
                    <measurement group_id="O3" value="0.0" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.44"/>
                    <measurement group_id="O2" value="-0.8" spread="1.60"/>
                    <measurement group_id="O3" value="-0.3" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.44"/>
                    <measurement group_id="O2" value="-1.2" spread="1.53"/>
                    <measurement group_id="O3" value="-0.5" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.49"/>
                    <measurement group_id="O2" value="-1.1" spread="1.68"/>
                    <measurement group_id="O3" value="-0.5" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.61"/>
                    <measurement group_id="O2" value="-1.1" spread="1.69"/>
                    <measurement group_id="O3" value="-0.7" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.31"/>
                    <measurement group_id="O2" value="-1.2" spread="1.70"/>
                    <measurement group_id="O3" value="-0.8" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.44"/>
                    <measurement group_id="O2" value="-1.0" spread="1.61"/>
                    <measurement group_id="O3" value="-1.1" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.56"/>
                    <measurement group_id="O2" value="-1.1" spread="1.58"/>
                    <measurement group_id="O3" value="-1.0" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.26"/>
                    <measurement group_id="O2" value="-0.9" spread="1.37"/>
                    <measurement group_id="O3" value="-1.0" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.51"/>
                    <measurement group_id="O2" value="-0.6" spread="1.28"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.38"/>
                    <measurement group_id="O2" value="-1.1" spread="1.38"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.45"/>
                    <measurement group_id="O2" value="-0.8" spread="1.36"/>
                    <measurement group_id="O3" value="-0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.39"/>
                    <measurement group_id="O2" value="-0.9" spread="1.52"/>
                    <measurement group_id="O3" value="-1.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.46"/>
                    <measurement group_id="O2" value="-1.5" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.47"/>
                    <measurement group_id="O2" value="-1.6" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="0.82"/>
                    <measurement group_id="O2" value="-0.7" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.53"/>
                    <measurement group_id="O2" value="-1.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-1.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-0.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 22 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.85"/>
                    <measurement group_id="O2" value="0.1" spread="1.82"/>
                    <measurement group_id="O3" value="0.4" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Follow Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.08"/>
                    <measurement group_id="O2" value="0.5" spread="1.43"/>
                    <measurement group_id="O3" value="0.7" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Cetuximab</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The pharmacokinetics (PK) set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Cetuximab</title>
          <population>The pharmacokinetics (PK) set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="841000" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="970000" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Encorafenib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Encorafenib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11300" spread="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6660" spread="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Binimetinib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Binimetinib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1960" spread="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1540" spread="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Metabolite of Binimetinib (AR00426032)</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Metabolite of Binimetinib (AR00426032)</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206" spread="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" spread="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195000" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199000" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3360" spread="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2490" spread="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="654" spread="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524" spread="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032)</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032)</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9" spread="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" lower_limit="1.83" upper_limit="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="1.00" upper_limit="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit=".883" upper_limit="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit=".950" upper_limit="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" lower_limit=".883" upper_limit="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit=".900" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032)</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032)</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit=".833" upper_limit="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit=".933" upper_limit="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" spread="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55400" spread="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post‑dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib</title>
        <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
        <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
        <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet, Doublet and Control Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib + cetuximab.
Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib</title>
          <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
          <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="14.9" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib</title>
        <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
        <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
        <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet, Doublet and Control Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib + cetuximab.
Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib</title>
          <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
          <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="17.7" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab</title>
        <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
        <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
        <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet, Doublet and Control Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.
Encorafenib + cetuximab.
Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab</title>
          <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
          <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0154" lower_limit="0.0114" upper_limit="0.0225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AE) were collected during the study (duration of safety lead-in and phase 3,approximately 12 months (up to 28 days per cycle)), which began in 09Oct2016 and still ongoing.</time_frame>
      <desc>An AE is defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occur after patient's signed informed consent has been obtained.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined Safety Lead-in</title>
          <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="E2">
          <title>Phase 3: Triplet Arm</title>
          <description>Encorafenib + binimetinib + cetuximab.
Encorafenib: Orally, once daily.
Binimetinib: Orally, twice daily.
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="E3">
          <title>Phase 3: Doublet Arm</title>
          <description>Encorafenib + cetuximab.
Encorafenib: Orally, once daily.
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="E4">
          <title>Phase 3:Control Arm</title>
          <description>Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
Cetuximab: Standard of care.
Irinotecan: Standard of care.
Folinic Acid: Standard of care.
5-Fluorouracil: Standard of care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Infusion-related reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastrointtestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rectal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Large intestine ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastrintestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bacteria sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="212" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="188" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>White blood cell count decrease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PPE syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rhinnorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Palmar-planar erythrodysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of the sponsor's agreements with its investigators may vary. However, the sponsor does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in the clinical trials.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Array BioPharma, Inc</organization>
      <phone>303-381-6604</phone>
      <email>clinicaltrials@arraybiopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

